Jump to content

HBL20016

Add links
From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

HBL20016
Clinical data
Other namesHBL-20016; 5-Methylthio-6-fluoro-N,N-dimethyltryptamine; 5-MeS-6-F-DMT
Drug classSerotonin receptor agonist; Serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist; Serotonergic psychedelic; Hallucinogen; Antiobsessional agent
Identifiers
  • 2-(6-fluoro-5-methylsulfanyl-1H-indol-3-yl)-N,N-dimethylethanamine
PubChem CID
Chemical and physical data
FormulaC13H17FN2S
Molar mass252.35 g·mol−1
3D model (JSmol)
  • CN(C)CCC1=CNC2=CC(=C(C=C21)SC)F
  • InChI=1S/C13H17FN2S/c1-16(2)5-4-9-8-15-12-7-11(14)13(17-3)6-10(9)12/h6-8,15H,4-5H2,1-3H3
  • Key:KQLJYTPVARKBRE-UHFFFAOYSA-N

HBL20016, also known as 5-methylthio-6-fluoro-N,N-dimethyltryptamine (5-MeS-6-F-DMT), is a non-selective serotonin receptor agonist and serotonergic psychedelic of the tryptamine family related to 5-MeO-DMT.[1][2] It is the 6-fluoro derivative of 5-MeS-DMT and the 5-methylthio derivative of 6-fluoro-DMT.[2]

The drug acts as an agonist of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors.[1][2] Its activational potencies (EC50Tooltip half-maximal effective concentration) are 645 nM for the serotonin 5-HT1A receptor, 1.64 nM for the serotonin 5-HT2A receptor, 3.42 nM for the serotonin 5-HT2B receptor, and 8.37 nM for the serotonin 5-HT2C receptor.[1][2] HBL20016 produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents, and hence would be expected to be hallucinogenic in humans.[1][2] The HTR induced by HBL20016 is comparable in magnitude to that occurring with psilocybin.[2] HBL20016 has shown antiobsessional-like effects in rodents, for instance against obsessive self-grooming.[1][2]

The chemical synthesis of HBL20016 has been described.[2]

HBL20016 was first described in the scientific literature in December 2024.[1][2] It was developed by Negev Labs and Parow Entheobiosciences.[1] A related drug, HBL20017 (4-F-5-MeS-DMT), which is a non-hallucinogenic agent with an otherwise mostly similar pharmacological profile, is under investigation for the potential treatment of obsessive–compulsive disorder (OCD).[1][2]

See also

References

  1. 1 2 3 4 5 6 7 8 Lerer B, Golding P, Brownstien M, Kozikowski A, Lifschytz T (December 2024). "ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P660. A Novel, Non-Hallucinogenic Psychedelic for the Treatment of Obsessive-Compulsive Disorder". Neuropsychopharmacology. 49 (Suppl 1): 418–594 (448–449). doi:10.1038/s41386-024-02013-y. PMID 39643635.
  2. 1 2 3 4 5 6 7 8 9 10 "Compounds and uses thereof as modulators of serotonin receptors". Google Patents. 10 April 2025. Retrieved 4 April 2026.
Retrieved from "https://en.wikipedia.org/w/index.php?title=HBL20016&oldid=1347114431"